Phase I of the first COVID-19 vaccine's clinical trials show that the vaccine is capable of generating an immune response against the novel coronavirus.

The U.S. Government Accountability Office has confirmed the generation of an immune response in the first COVID-19 vaccine's human trial.

The U.S. Government Accountability Office has confirmed the generation of an immune response in the first COVID-19 vaccine's human trial.The development of the Ad5 vectored COVID-19 vaccine started with identifying a target, such as a protein, that can induce an immune reaction. Researchers created a vaccine candidate similar to that target that would induce the production of antibodies effective against the coronavirus during April-May 2020.

The antibody response to the vaccine in the high dose group was slightly greater than that in the middle dose and low dose groups.

Based on the results, the researchers have said that the vaccine was well tolerated by the volunteers at all doses with no serious adverse events reported within 28 days of vaccination.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.